Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384721 | 1.00 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5384630 | 0.94 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5384621 | 0.94 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5393952 | 0.94 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5384564 | 0.93 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5390539 | 0.91 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5384637 | 0.91 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5387554 | 0.89 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5390119 | 0.89 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5398372 | 0.88 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1373258-B1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-6828333-B2 | Treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 10/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | PDE4A 2/4885PDE4B 3/4885PDE4C 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.